These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 2253227

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The effect of lonidamine alone and in combination with cisplatin on in vitro growth and viability of lung squamous cell carcinoma cell lines.
    Raaphorst GP, Ko D, Feeley MM, Danjoux CE, Maroun J, Evans WK.
    Anticancer Res; 1991 Feb 01; 11(1):41-7. PubMed ID: 2018379
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy: lonidamine, hyperthermia, and chemotherapy against the RIF-1 tumor in vivo.
    Ning SC, Hahn GM.
    Cancer Res; 1991 Nov 01; 51(21):5910-4. PubMed ID: 1718588
    [Abstract] [Full Text] [Related]

  • 6. Lonidamine can enhance the cytotoxic effect of cisplatin in human tumour cells and rodent cells.
    Raaphorst GP, Feeley MM, Heller DP, Danjoux CE, Martin L, Maroun JA, De Sanctis AJ.
    Anticancer Res; 1990 Nov 01; 10(4):923-7. PubMed ID: 2382989
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Morphological effects of lonidamine on two human-tumor cell culture lines.
    Szekely JG, Lobreau AU, Delaney S, Raaphorst GP, Feeley M.
    Scanning Microsc; 1989 Jun 01; 3(2):681-91; discussion 691-3. PubMed ID: 2814409
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Potentiation of radiation effects on two murine tumors by lonidamine.
    Kim JH, Alfieri AA, Kim SH, Young CW.
    Cancer Res; 1986 Mar 01; 46(3):1120-3. PubMed ID: 3943089
    [Abstract] [Full Text] [Related]

  • 14. [Effects of lonidamine alone or in combination with radiotherapy on survival and metabolism in human and rodent cell lines].
    Latz D, Flentje M, Eble M, Hör A, Wannenmacher M.
    Strahlenther Onkol; 1991 Dec 01; 167(12):716-22. PubMed ID: 1763408
    [Abstract] [Full Text] [Related]

  • 15. Cytotoxic effect of the association of BCNU with rhein or lonidamine on a human glioma cell line.
    Floridi A, Gentile PF, Bruno T, Fanciulli M, Paggi MG, Zeuli M, Benassi M.
    Anticancer Res; 1991 Dec 01; 11(2):789-92. PubMed ID: 1648334
    [Abstract] [Full Text] [Related]

  • 16. Preclinical screening for drugs effective against 5-fluorouracil-resistant cells with a murine L5178Y cell line in vitro.
    Hill BT.
    J Natl Cancer Inst; 1983 Aug 01; 71(2):335-40. PubMed ID: 6576190
    [Abstract] [Full Text] [Related]

  • 17. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A, Gamboa G, Nasseri A, Podnos YD, Emma D, Dorion G, Rawlings L, Carpenter PM, Bustamante A, Patel J, Rideout D.
    Gynecol Oncol; 1996 Feb 01; 60(2):203-12. PubMed ID: 8631539
    [Abstract] [Full Text] [Related]

  • 18. Growth inhibition by rhein and lonidamine of human glioma cells in vitro.
    Floridi A, Gentile FP, Bruno T, Castiglione S, Zeuli M, Benassi M.
    Anticancer Res; 1990 Feb 01; 10(6):1633-6. PubMed ID: 2285235
    [Abstract] [Full Text] [Related]

  • 19. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E.
    Cancer Res; 1986 Sep 01; 46(9):4379-83. PubMed ID: 3731096
    [Abstract] [Full Text] [Related]

  • 20. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y, Nakagawa K, Fujiwara Y, Sasaki Y, Minato K, Bungo M, Niimi S, Horichi N, Fukuda M, Saijo N.
    Cancer Res; 1989 Aug 01; 49(15):4098-102. PubMed ID: 2472873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.